CL2018000705A1 - Método de cristalización y biodisponibilidad - Google Patents
Método de cristalización y biodisponibilidadInfo
- Publication number
- CL2018000705A1 CL2018000705A1 CL2018000705A CL2018000705A CL2018000705A1 CL 2018000705 A1 CL2018000705 A1 CL 2018000705A1 CL 2018000705 A CL2018000705 A CL 2018000705A CL 2018000705 A CL2018000705 A CL 2018000705A CL 2018000705 A1 CL2018000705 A1 CL 2018000705A1
- Authority
- CL
- Chile
- Prior art keywords
- que
- zoledronico
- revestimiento
- enterico
- dosificacion
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220404P | 2015-09-18 | 2015-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000705A1 true CL2018000705A1 (es) | 2018-08-24 |
Family
ID=58289727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000705A CL2018000705A1 (es) | 2015-09-18 | 2018-03-16 | Método de cristalización y biodisponibilidad |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190083407A1 (enExample) |
| EP (1) | EP3362071A4 (enExample) |
| JP (1) | JP2018527392A (enExample) |
| KR (1) | KR20180053384A (enExample) |
| CN (1) | CN108601791A (enExample) |
| AU (1) | AU2016324482A1 (enExample) |
| CA (1) | CA2997378A1 (enExample) |
| CL (1) | CL2018000705A1 (enExample) |
| CO (1) | CO2018003558A2 (enExample) |
| MX (1) | MX2018002627A (enExample) |
| PE (1) | PE20180931A1 (enExample) |
| WO (1) | WO2017049294A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| CN108440449B (zh) * | 2018-04-17 | 2021-05-07 | 中国海洋大学 | 一种氢氯噻嗪与脯氨酸的共晶及其制备方法 |
| CN108558791B (zh) * | 2018-06-08 | 2021-05-07 | 中国海洋大学 | 一种乙酰唑胺与脯氨酸的共晶及其制备方法 |
| CN108570051B (zh) * | 2018-07-20 | 2021-02-02 | 中国科学院上海药物研究所 | 呋塞米-氨苯蝶啶盐、晶型i及其制备方法和应用 |
| CN108794418A (zh) * | 2018-09-18 | 2018-11-13 | 中国药科大学 | 一种缬沙坦烟酰胺共无定形物 |
| CN109568284B (zh) * | 2018-12-29 | 2020-04-24 | 广东中润药物研发有限公司 | 一种替诺福韦艾拉酚胺肠溶片及其制备方法 |
| CN109776430B (zh) * | 2019-02-01 | 2022-05-13 | 福建农林大学 | 一种磺胺二甲嘧啶共晶及其制备方法 |
| GB201907591D0 (en) * | 2019-05-29 | 2019-07-10 | Eolas Res Limited | Composition and use |
| CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| CN110372575A (zh) * | 2019-07-10 | 2019-10-25 | 复旦大学 | 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用 |
| CN111053755B (zh) * | 2019-12-31 | 2022-03-29 | 金日制药（中国）有限公司 | 一种高渗透性的头孢克肟胶囊制剂制备方法 |
| CN116917267B (zh) * | 2021-01-28 | 2025-08-12 | Imd制药公司 | 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法 |
| CN113181179A (zh) * | 2021-04-08 | 2021-07-30 | 深圳市泰力生物医药有限公司 | 一种二氢吡啶类钙拮抗剂盐组合物及其制备方法和应用 |
| KR102544543B1 (ko) * | 2021-04-29 | 2023-06-16 | 대봉엘에스 주식회사 | L,d-엘도스테인의 개별적 공결정화물 |
| US20260224490A1 (en) * | 2023-01-11 | 2026-08-06 | Board Of Regents, The University Of Texas System | Co-crystals with thin-film freeze-drying process to enhance delivery |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040220264A1 (en) * | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
| ES2322592T3 (es) * | 2003-07-03 | 2009-06-23 | Teva Pharmaceutical Industries Ltd. | Formas cristalinas de acido zoledronico, formas cristlinas de la sal sodica de zoledronato, sal sodica de zoledronato amorfa y procedimientos para su preparacion. |
| TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| WO2011014781A1 (en) * | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| KR101813728B1 (ko) * | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| EP2531200B1 (en) * | 2010-02-06 | 2017-07-12 | Grünenthal GmbH | Crystallization method and bioavailability |
| KR20120105738A (ko) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | 장용코팅된 경구용 제제 |
| PL2849758T3 (pl) * | 2012-05-14 | 2018-08-31 | Antecip Bioventures Ii Llc | Kompozycje zawierające kwas zoledronowy lub pokrewne związki do uśmierzania bólu zapalnego i stanów powiązanych |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US8802658B2 (en) * | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US20140348916A1 (en) * | 2014-08-11 | 2014-11-27 | Antecip Bioventures Ii Llc | Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer |
-
2016
- 2016-09-19 MX MX2018002627A patent/MX2018002627A/es unknown
- 2016-09-19 WO PCT/US2016/052492 patent/WO2017049294A1/en not_active Ceased
- 2016-09-19 AU AU2016324482A patent/AU2016324482A1/en not_active Abandoned
- 2016-09-19 CA CA2997378A patent/CA2997378A1/en not_active Abandoned
- 2016-09-19 KR KR1020187010719A patent/KR20180053384A/ko not_active Withdrawn
- 2016-09-19 PE PE2018000403A patent/PE20180931A1/es unknown
- 2016-09-19 EP EP16847548.1A patent/EP3362071A4/en not_active Withdrawn
- 2016-09-19 JP JP2018514876A patent/JP2018527392A/ja active Pending
- 2016-09-19 CN CN201680067559.3A patent/CN108601791A/zh active Pending
-
2018
- 2018-03-15 US US15/922,278 patent/US20190083407A1/en not_active Abandoned
- 2018-03-16 CL CL2018000705A patent/CL2018000705A1/es unknown
- 2018-04-04 CO CONC2018/0003558A patent/CO2018003558A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3362071A4 (en) | 2019-07-17 |
| JP2018527392A (ja) | 2018-09-20 |
| WO2017049294A1 (en) | 2017-03-23 |
| CO2018003558A2 (es) | 2018-07-19 |
| CA2997378A1 (en) | 2017-03-23 |
| AU2016324482A1 (en) | 2018-03-29 |
| MX2018002627A (es) | 2018-12-17 |
| CN108601791A (zh) | 2018-09-28 |
| EP3362071A1 (en) | 2018-08-22 |
| PE20180931A1 (es) | 2018-06-08 |
| KR20180053384A (ko) | 2018-05-21 |
| US20190083407A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018003558A2 (es) | Método de cristalización y biodisponibilidad | |
| BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| IL258464A (en) | Pharmaceutical compositions for oral administration of peptide drugs | |
| MA43574A (fr) | Compositions ayant des amplificateurs de perméation pour l'administration de médicaments | |
| EP3600563C0 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID | |
| CO2019000643A2 (es) | Formulaciones gastrorretentivas orales y usos de las mismas | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| MX387604B (es) | Formulaciones cannabinoides estables. | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| BR112017003219A2 (pt) | formulação de acetato de abiraterona e métodos de uso | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| MX385925B (es) | Oritavancina de alta pureza y método para producir la misma. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
| MY191980A (en) | Formulations containing an extract of echinacea and linoleic acid derivatives | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| HUE057871T2 (hu) | Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók | |
| BR112014027653A2 (pt) | formulações para a liberação dos ingredientes ativos | |
| MX384254B (es) | Formulaciones para mejorar la eficacia de farmacos hidrofobicos. | |
| BR112018071363A2 (pt) | composições farmacêuticas orais de nicotinamida |